Pharmaceutical Repurposing Strategies for Metabolic Disorders: Insights from Mendelian Randomization Studies
Shixuan, Z.; Xiaoxi, H.; Dandan, H.; Xiaoru, S.; Dayan, S.
Show abstract
Metabolic disorders (MDs) are a group of medical conditions that impact the metabolism. These complex processes may have common characteristics among various diseases, thereby suggesting the potential of drug repurposing. Employing Mendelian Randomization (MR), we constructed a causal network between 2,478 targetable drug-gene expressions (eQTLs) and 30 broadly reported metabolic disorders. Our study identified 499 drug target genes significantly associated with 27 metabolic disorders (|MR coefficient| > 0.2). Pathway enrichment analysis of drug target genes indicates that regulation of response stimulus may serve as a common pathway across 14 diseases. Based on 53 commonly used clinical drugs for 18 diseases, we elucidated novel therapeutic mechanisms of some drugs, such as the potential of Valproic Acid to treat Schizophrenia by affecting key genes in Alcoholism, SLC29A1, and HDAC4. Furthermore, we identified potential for drug repurposing in four diseases, with Manic Episode and Type 1 Diabetes sharing four novel drugs: Cannabidiol, Doxorubicin, Genistein, and Propylthiouracil. Additionally, we predicted 189 potential therapeutic drugs affecting the causal genes of diseases. Overall, we established a causal network between metabolic disorders and drug target genes, explored possible pathways for drug action on disease treatment, and proposed drug repurposing strategies for four diseases. HighlightsO_LITo the best of our understanding, the manuscript we have submitted delineates the inaugural drug-gene causal network tailored for Metabolic Disorders (MDs), covering an array of 30 diseases. C_LIO_LIThis investigation unveils potential novel drug mechanisms aimed at treating MDs, marking a pioneering exploration in this domain. C_LIO_LIWe introduce strategies for the repurposing of drugs targeting four specific MDs, suggesting innovative approaches to treatment. C_LIO_LIThe findings are presented through an easily navigable web interface, enabling thorough examination by users (https://quantlifebits.shinyapps.io/mrmetabopharm/). C_LI
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Genome-wide association study of COVID-19 Breakthrough Infections and genetic overlap with other diseases: A study of the UK Biobank 93%
- DReAmocracy: A Method to Capitalize on Prior Drug Discovery Efforts to Highlight Candidate Drugs for Repurposing 93%
- Small-molecule inhibitors of the RNA m6A demethylase FTO potently support the survival of dopamine neurons 92%
Similar papers in this journal
Similar papers in this journal
- Neuroactive metabolites and bile acids are altered in extremely premature infants with brain injury 90%
- Treatment with commonly used antiretroviral drugs induces a type I/III interferon signature in the gut in the absence of HIV infection 90%
- Acetaminophen inhibits diacylglycerol lipase synthesis of 2-arachidonoyl glycerol: implications for nociception 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.